Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O6IZ
|
||||
| Former ID |
DAP001408
|
||||
| Drug Name |
Naphazoline
|
||||
| Synonyms |
Antan; Clearine; Nafazolin; Nafazolina; Nafazoline; Naphazolinum; Naphthizine; Opcon; Nafazolina [DCIT]; Nafazoline [Spanish]; Naphazoline Monohydrochloride; Naphazolinum [Latin]; Enamine_000333; Alpha-Naphthylmethyl imidazoline; Ciba 2020/R; Nafazolin (TN); Naphazoline (INN); Naphazoline [INN:BAN]; Naphazolinum [INN-Latin]; AK-968/41090774; 2-(1-Naphthylmethyl)-2-imidazoline; 2-(1-Naphthylmethyl)-4,5-dihydro-1H-imidazole; 2-(Naphthyl-(1')-methyl)imidazolin; 2-(Naphthyl-(1')-methyl)imidazolin [German]; 2-(alpha-Naphthylmethyl)-imidazoline; 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole; 4,5-Dihydro-2-(1-naphthylmethyl)imidazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Corneal vascularity; Hyperaemia; Itching [ICD10:L29] | Approved | [1] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Allergan Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H14N2
|
||||
| InChI |
InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16)
|
||||
| InChIKey |
CNIIGCLFLJGOGP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 835-31-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3137457, 4405740, 7980082, 8152738, 10536779, 11112411, 11335631, 11342564, 11360870, 11363869, 11366431, 11368993, 11371665, 11373734, 11377155, 11461842, 11466074, 11467194, 11484744, 11485828, 11488870, 11490329, 11491883, 11494789, 14822445, 26751615, 29223533, 47291085, 47662225, 47810702, 47885358, 48035054, 48110408, 48110409, 49698318, 49980699, 50100430, 50810620, 57322271, 57937910, 85209585, 85788822, 88684032, 92244917, 92309071, 93624349, 96024941, 99443263, 103202876, 103916289
|
||||
| SuperDrug ATC ID |
R01AA08; R01AB02; S01GA01
|
||||
| SuperDrug CAS ID |
cas=000835314
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.